39 patents
Page 2 of 2
Utility
Film formulations containing dexmedetomidine and methods of producing them
15 Nov 22
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 23 Dec 21
Utility
Film formulations containing dexmedetomidine and methods of producing them
25 Oct 22
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 17 Jul 20
Utility
Treatment of Sarcoma Using Immunomodulation
18 Aug 22
The present disclosure provides a method for treating a subject afflicted with sarcoma selected from soft tissue sarcoma (such as liposarcoma, myxoid sarcoma) and osteosarcoma by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab, wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.3 mg twice daily on one or more days of a treatment cycle.
Vincent J. O'NEILL
Filed: 17 Feb 22
Utility
Dexmedetomidine Treatment Regimens
21 Jul 22
Disclosed herein are methods of administering dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject.
Adedayo Adedoyin, Jeffrey R. Sabados, Lavanya Rajachandran, Robert Risinger
Filed: 4 Jan 22
Utility
Systems and Methods of Using Machine Learning to Detect and Predict Emergence of Agitation Based on Sympathetic Nervous System Activities
30 Jun 22
In some embodiments, a method includes receiving first physiological data of sympathetic nervous system activity and establishing a baseline value of at least one physiological parameter by training at least one machine learning model using the first physiological data.
Frank D. YOCCA, Michael De Vivo, Robert Risinger, Subhendu Seth, Martin Majernik, Daniel R. Karlin, Jamileh Jemison, Alexander Wald, Miguel Amável Dos Santos Pinheiro
Filed: 18 Mar 22
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
26 May 22
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 23 Dec 21
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
14 Apr 22
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar KAKUMANU, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 23 Dec 21
Utility
Novel Approach for Treatment of Cancer Using Immunomodulation
24 Mar 22
The present disclosure provides a regimen for treating a subject afflicted with prostate cancer by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab.
Vincent J. O'NEILL
Filed: 10 Dec 19
Utility
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
3 Feb 22
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA
Filed: 7 Oct 21
Utility
Combination Therapies for Treating Disease Using an Innate Immunity Modifier and an OX40 Agonist
27 Jan 22
The present disclosure provides methods of treating cancer comprising administering a selective dipeptidyl peptidase inhibitor and an OX40 agonist with or without one or more immune checkpoint inhibitors to a subject with cancer.
Vimal D. MEHTA, Luca RASTELLI, John MACDOUGALL, Snigdha GUPTA
Filed: 10 Dec 19
Utility
Predictive and Diagnostic Methods for Prostate Cancer
18 Nov 21
The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients.
Krishnan NANDABALAN, Luca RASTELLI
Filed: 9 Jan 18
Utility
Methods for Treating Agitation Using Dexmedetomidine Hydrochloride
2 Sep 21
The present disclosure relates to the treatment of agitation or signs of agitation in certain human subjects, including subjects with a neurodegenerative, neuropsychiatric or opioid withdrawal disorder, by administering dexmedetomidine hydrochloride by the intravenous route.
Frank D. YOCCA, Michael DEVIVO
Filed: 26 Jun 19
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
18 Mar 21
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 24 Nov 20
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
4 Nov 20
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
Filed: 16 Jul 20
Utility
Methods and Compositions for Treating Cancer by Modifying Multiple Arms of the Immune System
7 Oct 20
Provided herein are combination methods and compositions for cancer therapies.
Krishnan NANDABALAN, Vimal D. MEHTA, Luca RASTELLI, John MACDOUGALL, Jonathan ZALEVSKY, Deborah H. CHARYCH
Filed: 12 Nov 18
Utility
Film formulations containing dexmedetomidine and methods of producing them
5 Oct 20
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 25 Jun 19
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
1 Jan 20
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
Filed: 25 Jun 19
Utility
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
4 Dec 19
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA
Filed: 28 Dec 17
Utility
Use of SRC Family Kinase Inhibitor In Ribosomal Disorder
2 Oct 19
The present disclosure provides methods and compositions for the use of a Src family kinase (SFK) inhibitor for the treatment of anemia associated with ribosomal disorders, such as diamond blackfan anemia.
Krishnan NANDABALAN
Filed: 8 Jun 17